Cardiovascular disease and osteoporosis: is there a link between lipids and bone?

Ann Clin Biochem 2002;39:203-210
doi:10.1258/0004563021902134
© 2002 Association for Clinical Biochemistry

 

This Article
Right arrow

Full Text (PDF)

Right arrow
Alert me when this article is cited
Right arrow
Alert me if a correction is posted
Services
Right arrow
Email this article to a friend
Right arrow

Similar articles in this journal

Right arrow
Similar articles in PubMed
Right arrow
Alert me to new issues of the journal
Right arrow
Download to citation manager
Right arrow
Citing Articles
Right arrow
Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow
Articles by Burnett, J. R
Right arrow
Articles by Vasikaran, S. D
Right arrow Search for Related Content
PubMed
Right arrow
PubMed Citation
Social Bookmarking

What’s this?

Review Articles


John R Burnett and
Samuel D Vasikaran


Department of Core Clinical Pathology & Biochemistry Division of Laboratory Medicine Royal Perth Hospital, GPO Box X2213, Perth, WA 6847, Australia and Department of Pathology University of Western Australia Perth, Australia;
Department of Core Clinical Pathology & Biochemistry Division of Laboratory Medicine Royal Perth Hospital, GPO Box X2213, Perth, WA 6847, Australia and Department of Pathology University of Western Australia Perth, Australia

Atherosclerotic heart disease and osteoporosis are both diseases of old age. Evidence is accumulating for a link between vascular and bone disease. Calcification is a common feature of atherosclerotic plaques, and osteoporosis is associated with both atherosclerosis and vascular calcification. However, the relationship of vascular calcification to the pathogenesis of atherosclerosis remains incompletely understood. Hormone replacement therapy has beneficial effects in the prevention of both atherosclerosis and osteoporosis. Bisphosphonates inhibit bone resorption and are used in the treatment of osteoporosis, whereas the statins inhibit cholesterol biosynthesis and are used for the treatment of atherosclerosis. We have reviewed recent advances in the knowledge of the actions of bisphosphonates and statins at the cellular, molecular and end-organ levels in order to examine the relationship between cardiovascular disease and osteoporosis and to explore the link between lipids and bones. These studies suggest that the mechanism of actions of these two classes of drugs at the cellular level may not be mutually exclusive. There are some early clinical data to complement these findings, suggesting that statins increase bone density and bisphosphonates may have a beneficial effect in vivo on plasma lipid levels and on the atherosclerotic process.Properly designed prospective studies that examine the effectof statins on bone density and fractures, as well as the effectsof bisphosphonates on lipid profiles, atherosclerotic progressionand cardiovascular morbidity and mortality are needed to defineclearly the clinical effects and potential new roles for theseagents.


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What’s this?






This article has been cited by other articles:


R. H. Samson
The Role of Statin Drugs in the Management of the Peripheral Vascular Patient
Vascular and Endovascular Surgery,

August 1, 2008;

42(4):

352 – 366.

[Abstract]
[PDF]